United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). - patients with hypercalcemia. patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1) ] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. calcium acetate capsules contain calcium acetate and is excreted in human milk. human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored. safety and effectiveness in pediatric patients have not been established. clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other clinical experience has not identified differences in responses between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate.  animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women.  patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] .  maintenance of normal serum calcium levels is important for maternal and fetal well being.  hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism.  calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being.  hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are

United States - English - NLM (National Library of Medicine)

american regent, inc. - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - calcium chloride 100 mg in 1 ml - calcium chloride is indicated in the immediate treatment of hypocalcemic tetany.  other therapy, such as parathyroid hormone or vitamin d, may be indicated according to the etiology of the tetany. it is also important to institute oral calcium therapy as soon as practicable. calcium salts have been used as adjunctive therapy in a number of conditions, including the following: - insect bites or stings, such as black widow spider bites. sensitivity reactions, particularly when characterized by urticaria. as an aid in the treatment of depression due to overdosage of magnesium sulfate. as an aid in the management of the acute symptoms in lead colic. in cardiac resuscitation, particularly after open heart surgery, calcium chloride has been used when epinephrine has failed to improve weak or ineffective myocardial contractions. insect bites or stings, such as black widow spider bites. sensitivity reactions, particularly when characterized by urticaria. as an aid in the treatment of depression due to overdo

United States - English - NLM (National Library of Medicine)

hospira, inc. - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - calcium chloride 100 mg in 1 ml - calcium chloride injection is indicated for the treatment of adult and pediatric patients with acute symptomatic hypocalcemia. limitations of use the safety and effectiveness of calcium chloride injection for long-term use has not been established. calcium chloride injection is contraindicated in: newborns (up to 28 days of age) if they require (or are expected to require) ceftriaxone intravenous treatment because of the risk of precipitation of ceftriaxone-calcium, regardless of whether these products would be received at different times or through separate intravenous lines [see warnings and precautions (5.1)] .       risk summary administration of calcium chloride injection for the treatment of acute symptomatic hypocalcemia during pregnancy is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. there are risks to the mother and the fetus associated with development of hypocalcemia during pregnancy (see clinical considerations) . animal reproduction studies have n

Israel - English - Ministry of Health

lapidot medical import and marketing ltd - calcium gluconate - solution for injection - calcium gluconate 0.94 g / 10 ml - calcium gluconate - calcium gluconate - treatment of acute symptomatic hypocalcaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - calcium chloride dihydrate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - parental administration of calcium is indicated in the treatment of hypocalcaemia where rapid increase in plasma calcium is required, such as in hypocalcaemic tetany and tetany due to parathyroid deficiency. intravenous calcium is also indicated to antagonise the cardiotoxicity of hyperkalaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - calcium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: vanillin; saccharin - calcium resonium is an ion-exchange resin. it is recommended for the treatment of hyperkalaemia associated with anuria and severe oliguria.,it is also used to treat hyperkalaemia in patients requiring dialysis and in patients on regular haemodialysis or on prolonged peritoneal dialysis.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sykes vet (international) pty. ltd. - calcium as calcium carbonate, di-calcium phosphate and c; cobalt as cobalt (ii) sulfate; copper (cu) present as copper sulfate; iron as ferrous sulfate; magnesium as magnesium sulfate; manganese as manganese (ii) sulfate; zinc as zinc oxide; vitamin a; vitamin c = ascorbic acid; vitamin d3; vitamin e; vitamin k3 - oral powder, pre-mix - calcium as calcium carbonate, di-calcium phosphate and c mineral-calcium active 333.3 g/kg; cobalt as cobalt (ii) sulfate mineral-cobalt active 1.1 g/kg; copper (cu) present as copper sulfate mineral-copper active 1.2 g/kg; iron as ferrous sulfate mineral-iron active 3.7 g/kg; magnesium as magnesium sulfate mineral-magnesium active 17.6 g/kg; manganese as manganese (ii) sulfate mineral-manganese active 7.3 g/kg; zinc as zinc oxide mineral-zinc active 3.2 g/kg; vitamin a vitamin-a active 900000.0 iu/kg; vitamin c = ascorbic acid vitamin-c active 5390.0 mg/kg; vitamin d3 vitamin-d3 active 1200.0 mg/kg; vitamin e vitamin-e active 2600.0 iu/kg; vitamin k3 vitamin-k3 active 750.0 mg/kg - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - calcium supplement | iron deficiency | phosphorus deficiency | vitamin & mineral deficiency | anaemia

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - calcium folinate pentahydrate 12.71 mg/ml equivalent to 10 mg/ml folinic acid - concentrate for injection - 10 mg/ml - active: calcium folinate pentahydrate 12.71 mg/ml equivalent to 10 mg/ml folinic acid excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - · as rescue therapy to reduce toxicity following high-dose methotrexate therapy. · has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions · overdosage of methotrexate and in impaired methotrexate elimination · reducing the toxicity and circumventing the effect of folic acid antagonists